Literature DB >> 20308376

Mutant prevention concentrations of four carbapenems against gram-negative rods.

Kim Credito1, Klaudia Kosowska-Shick, Peter C Appelbaum.   

Abstract

We tested the propensities of four carbapenems to select for resistant Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii mutants by determining the mutant prevention concentrations (MPCs) for 100 clinical strains with various ss-lactam phenotypes. Among the members of the Enterobacteriaceae family and A. baumannii strains, the MPC/MIC ratios were mostly 2 to 4. In contrast, for P. aeruginosa the MPC/MIC ratios were 4 to > or =16. The MPC/MIC ratios for beta-lactamase-positive K. pneumoniae and E. coli isolates were much higher (range, 4 to >16 microg/ml) than those for ss-lactamase-negative strains.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308376      PMCID: PMC2876356          DOI: 10.1128/AAC.00033-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.

Authors:  Elizabeth D Hermsen; Laurie B Hovde; George N Konstantinides; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

2.  Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.

Authors:  Glen T Hansen; Xilin Zhao; Karl Drlica; Joseph M Blondeau
Journal:  Int J Antimicrob Agents       Date:  2006-01-19       Impact factor: 5.283

3.  Overstretching the mutant prevention concentration.

Authors:  David M Livermore
Journal:  J Antimicrob Chemother       Date:  2003-09-12       Impact factor: 5.790

Review 4.  Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature.

Authors:  M E Falagas; P Kopterides
Journal:  J Hosp Infect       Date:  2006-07-05       Impact factor: 3.926

Review 5.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

6.  Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Infect Dis       Date:  2002-01-31       Impact factor: 5.226

7.  Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.

Authors:  Xilin Zhao; William Eisner; Nathan Perl-Rosenthal; Barry Kreiswirth; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

8.  Resistance development profiling of piperacillin in combination with the novel {beta}-lactamase inhibitor BLI-489.

Authors:  Alexey Ruzin; Peter J Petersen; C Hal Jones
Journal:  J Antimicrob Chemother       Date:  2009-12-11       Impact factor: 5.790

9.  Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli.

Authors:  G A Jacoby; P Han
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

10.  In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.

Authors:  Kazuko Yamamoto; Katsunori Yanagihara; Kazuyuki Sugahara; Yoshifumi Imamura; Masafumi Seki; Koichi Izumikawa; Hiroshi Kakeya; Yoshihiro Yamamoto; Yoichi Hirakata; Shimeru Kamihira; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

View more
  8 in total

Review 1.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

2.  Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.

Authors:  Xin Li; Lin Wang; Xian-Jia Zhang; Yang Yang; Wei-Tao Gong; Bin Xu; Ying-Qun Zhu; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

3.  Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.

Authors:  Chengchun Sun; Junwen Hao; Meiqin Dou; Yanwen Gong
Journal:  J Antibiot (Tokyo)       Date:  2014-11-05       Impact factor: 2.649

4.  Fluoroquinolone resistance mechanism of clinical isolates and selected mutants of Pasteurella multocida from bovine respiratory disease in China.

Authors:  Ling-Cong Kong; Duo Gao; Yun-Hang Gao; Shu-Ming Liu; Hong-Xia Ma
Journal:  J Vet Med Sci       Date:  2014-09-17       Impact factor: 1.267

5.  Mutant prevention concentrations of imipenem and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  E Dahdouh; S H Shoucair; S E Salem; Z Daoud
Journal:  ScientificWorldJournal       Date:  2014-12-30

6.  Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates.

Authors:  Mona I Shaaban; Mohamed A Shaker; Fatma M Mady
Journal:  J Nanobiotechnology       Date:  2017-04-11       Impact factor: 10.435

7.  In vitro susceptibility of four antimicrobials against Riemerella anatipestifer isolates: a comparison of minimum inhibitory concentrations and mutant prevention concentrations for ceftiofur, cefquinome, florfenicol, and tilmicosin.

Authors:  Yafei Li; Yanan Zhang; Huanzhong Ding; Xian Mei; Wei Liu; Jiaxiong Zeng; Zhenling Zeng
Journal:  BMC Vet Res       Date:  2016-11-09       Impact factor: 2.741

Review 8.  Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Authors:  J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver
Journal:  Rev Esp Quimioter       Date:  2018-02-23       Impact factor: 1.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.